Lytic activity, stability, biofilm disruption capabilities, and genomic characterization of two bacteriophages active against respiratory MRSA
Koomba kaat 1 and Biyabeda mokiny 1 are promising candidates for phage therapy. Their efficacy against clinical S. aureus isolates, ability to break down biofilm, and stability for airway implementation, positions them as valuable tools for addressing persistent airway infections caused by S. aureus.
Authors
- Anthony Kicic (ORCID: https://orcid.org/0000-0002-0008-9733)
- Stephen M. Stick (ORCID: https://orcid.org/0000-0002-5386-8482)
- Alexander N. Larcombe (ORCID: https://orcid.org/0000-0003-4196-4482)
- Luke W. Garratt (ORCID: https://orcid.org/0000-0001-9381-326X)
- Joshua J. Iszatt (ORCID: https://orcid.org/0000-0002-6394-5058)
Institutions
- The Kids Research Institute Australia (AU)
- The University of Western Australia (AU)
- Curtin University (AU)
- Princess Margaret Hospital for Children (AU)
- Government of Western Australia Department of Health (AU)
- Perth Children's Hospital
Publication Details
- Journal
- Journal of Applied Microbiology
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1093/jambio/lxaf081
- Citations
- 1
- Primary Topic
- Bacteriophages and microbial interactions
- Type
- article
- Field-Weighted Citation Impact
- 1.72